评估 XmAb24306 联合 Cevostamab 在复发/难治性多发性骨髓瘤参与者中的安全性、药代动力学和活性的剂量递增研究
一项 Ib 期、开放标签、多中心剂量递增研究,以评估 XmAb24306 联合 Cevostamab 在复发/难治性多发性骨髓瘤患者中的安全性、药代动力学和活性
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Vejle、丹麦、7100
- Sygehus Lillebaelt - Vejle Sygehus
-
-
-
-
-
Petah Tikva、以色列、4941492
- Rabin Medical Center-Beilinson Campus
-
Tel Aviv、以色列、64239
- Tel Aviv Sourasky Medical Center PPDS
-
-
-
-
-
Athens、希腊、106 76
- Evangelismos General Hospital of Athens
-
Athens、希腊、115 28
- University of Athens, Hematological Clinic,
-
-
-
-
-
Oslo、挪威、N - 0424
- Oslo University Hospital Rikshospitalet
-
-
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne、Victoria、澳大利亚、3004
- Alfred Hospital
-
Melbourne、Victoria、澳大利亚、3000
- Peter Maccallum Cancer Centre
-
-
-
-
-
Valencia、西班牙、46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- Clinica Universidad de Navarra
-
-
-
-
-
Seoul、韩国、05505
- Asan Medical Center - PPDS
-
Seoul、韩国、03722
- Severance Hospital, Yonsei University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody.
- Documented evidence of progressive disease on or after the last prior therapy, or participants who were intolerant to the last prior therapy.
- Measurable disease, as defined by the protocol
- Participants agree to follow contraception or abstinence requirements as defined in the protocol
Exclusion Criteria:
- Any anti-cancer therapy within 3 weeks prior to initiation of study treatment with exception defined by the protocol
- Participants with autologous stem cell transplantation (SCT) within 100 days prior to first dose of study treatment
- Participants with prior allogeneic SCT or solid organ transplantation
- Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
- Active or history of autoimmune disease
- Participants with current or history of Central Nervous System (CNS) disease, or current CNS involvement by Multiple Myeloma (MM)
- Significant cardiovascular disease
- Participants with known clinically significant liver disease
- Symptomatic active pulmonary disease requiring supplemental oxygen
- Known active infection requiring intravenous anti-microbial therapy within 14 days prior to first study drug administration
- Any episode of active, symptomatic COVID-19 infection, or requiring treatment with IV antivirals for COVID-19 (not including COVID-19 primary prophylaxis) within 14 days, prior to first study treatment
- Other protocol defined inclusion/exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Dose-Escalation and Expansion: XmAb24306+Cevostamab
Participants will receive escalating doses of XmAb24306 with a fixed dose regimen for cevostamab up to the maximum tolerated dose (MTD). After dose escalation has been completed, up to two expansion cohorts each investigating different XmAb24306 doses in combination with cevostamab may be enrolled. |
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
其他名称:
Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
其他名称:
XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
其他名称:
|
|
实验性的:Arm B: Single-Agent Cevostamab Expansion
Participants will receive cevostamab alone. |
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
其他名称:
Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Adverse Events (AEs)
大体时间:Up to approximately 3 years
|
Adverse events will be reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), and Cytokine Release Syndrome (CRS), will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria. |
Up to approximately 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
XmAb24306 的血清浓度
大体时间:最长约 3 年
|
最长约 3 年
|
|
|
Cevostamab 的血清浓度
大体时间:最长约 3 年
|
最长约 3 年
|
|
|
具有 XmAb24306 和 Cevostamab 抗药抗体 (ADA) 的参与者百分比
大体时间:最长约 3 年
|
最长约 3 年
|
|
|
Objective Response Rate (ORR)
大体时间:Up to approximately 3 years
|
ORR will be determined by the investigator according to International Myeloma Working Group (IMWG) criteria. |
Up to approximately 3 years
|
|
Rate of Complete Response (CR)/ Stringent Complete Response (sCR)
大体时间:Up to approximately 3 years
|
Rate of CR/sCR will be determined by the investigator. |
Up to approximately 3 years
|
|
Rate of Very Good Partial Response (VGPR)
大体时间:Up to approximately 3 years
|
Rate of VGPR will be determined by the investigator. |
Up to approximately 3 years
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- GO43980
- 2022-001204-18 (EudraCT编号)
- 2023-505212-38-00 (其他标识符:EU CT Number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.